Dynavax Technologies | DVAX - Ebitda


Dynavax Technologies reported $35.53M in EBITDA for its fiscal quarter ending in September of 2025.



Ebitda Change Date
AbbVie USD 3.52B 828M Sep/2025
Adma Biologics USD 73.59M 14.85M Dec/2025
Agenus USD -10.11M 19.02M Mar/2025
Amgen USD 5.14B 775M Dec/2025
AstraZeneca USD 5.23B 272M Sep/2025
Biogen USD 573.2M 253.7M Dec/2025
BioMarin Pharmaceutical USD -24.17M 18.91M Dec/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Gilead Sciences USD 4.03B 628M Sep/2025
Glaxosmithkline GBP 4.75B 1.52B Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Nektar Therapeutics USD -31.81M 70K Sep/2023
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
Novartis USD 4.77B 1.11B Dec/2025
Pfizer USD 6.08B 351M Sep/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sarepta Therapeutics USD -168.03M 294.45M Sep/2025
TG Therapeutics USD 32.69M 5M Sep/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025